AUTHORS
Doug W. Sborov, MD, MS, Susan Geyer, PhD2, Michael Linden, MD3, Jens Hillengass, MD, PhD4, Constantine Mitsiades, MD, PhD5, Francesco Maura, MD6, Rachel Wills, MS7, Shira Dinner, MD8, Brian Ko, MD9, Amrita Krishnan, MD, FACP10, S. Vincent Rajkumar, MD11, Peter Voorhees, MD12, Saad Z. Usmani, MD13
AFFILIATIONS
1 Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
6 Memorial Sloan Kettering, New York, New York, United States
7 Alliance Protocol Operations Office, University of Chicago, Chicago, Illinois, United States
8 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
9 National Institutes of Health - National Cancer Institute, Rockville, Maryland, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States
13 Memorial Sloan Kettering, New York, New York, United States
ABSTRACT
Introduction/Background
Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell neoplasm characterized by circulating plasma cells, frequent extramedullary disease, and inferior survival outcomes compared with multiple myeloma. Contemporary series report median overall survival ranging from approximately 18–36 months despite the use of proteasome inhibitor- and immunomodulatory drug-based approaches and autologous stem cell transplantation. Prospective studies in pPCL remain limited, and outcomes remain poor despite intensified treatment strategies, highlighting a significant unmet need for novel therapeutic approaches. The QUANTUM trial (A062401; NCT07605416) is a prospective randomized study was developed to evaluate whether incorporation of B-cell maturation antigen (BCMA)-directed therapy into frontline management can improve outcomes in transplant-eligible patients with newly diagnosed pPCL; the trial is currently open to accrual.
Methods
Alliance A062401 (QUANTUM; NCT07605416) is a prospective randomized phase II study enrolling transplant-eligible patients with newly diagnosed pPCL. Eligible patients must have >5% circulating plasma cells at diagnosis, measurable disease according to International Myeloma Working Group criteria, fitness for autologous stem cell transplantation, and receipt of no more than one prior cycle of induction therapy. Participants will receive D-KRd (daratumumab (D), carfilzomib (K), lenalidomide (R), and dexamethasone (d)) quadruplet induction followed by autologous stem cell transplantation, and will be randomized for consolidation with D-KRd or teclistamab, followed by KR doublet maintenance. The primary endpoint is overall survival. Secondary endpoints include safety and tolerability, response rates (overall response rate, very good partial response, complete response, stringent complete response), progression-free survival, time to response, time to progression, duration of response, and measurable residual disease (MRD) negativity at predefined treatment landmarks. Planned enrollment is 64 patients (32 per arm), providing ≥80% power to detect a hazard ratio of 0.50 using a one-sided α of 0.10. Correlative analyses include central pathology review of diagnostic bone marrow biopsies, aspirates, and peripheral blood smears, longitudinal circulating plasma cell assessment, genomic profiling, biobanking, and imaging-based evaluation at serial disease milestones.
Conclusion
pPCL remains a disease with poor outcomes and limited prospective evidence to guide management. This randomized phase 2 study evaluates a frontline strategy incorporating BCMA-directed consolidation into transplant-based therapy with the goal of improving survival and depth of response. Correlative analyses may further define mechanisms of resistance, disease biology, and predictors of durable remission in this high-risk population.
Support
The clinical trial is sponsored by the National Cancer Institute, part of National Institutes of Health, and led by the Alliance for Clinical Trials in Oncology (ALLIANCE) and conducted by the NCI’s National Clinical Trials Network (NCTN). Janssen Research and Development, LLC provided support through a Cooperative Research and Development Agreement with NCI. The clinical trial is supported by NCI U10CA180821,U10CA180882.
DISCLOSURES
Doug W. Sborov, MD, MS: BinayTara Foundation - Honoraria; Johnson & Johnson - Research Funding; Pfizer - Research Funding; Regeneron - Research Funding; Opna Bio - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Caribou - Consultancy (Includes expert testimony)